ICD↔CPT crosswalk
CPT 0178U: ICD-10 codes that support medical necessity
These ICD-10-CM diagnoses support medical necessity for CPT 0178U under Medicare coverage policies (LCDs, NCDs, and Billing & Coding articles). Billing CPT 0178U with a diagnosis that isn't covered typically denies as CARC 50 — not medically necessary.
National approximation. Coverage varies by MAC and state — confirm against the specific LCD/NCD and article that applies to your jurisdiction and date of service.
| ICD-10 | Description |
|---|---|
| B44.0 | Invasive pulmonary aspergillosis |
| H10.411 | Chronic giant papillary conjunctivitis, right eye |
| H10.412 | Chronic giant papillary conjunctivitis, left eye |
| H10.413 | Chronic giant papillary conjunctivitis, bilateral |
| H10.44 | Vernal conjunctivitis |
| H10.45 | Other chronic allergic conjunctivitis |
| H65.411 | Chronic allergic otitis media, right ear |
| H65.412 | Chronic allergic otitis media, left ear |
| H65.413 | Chronic allergic otitis media, bilateral |
| J30.1 | Allergic rhinitis due to pollen |
| J30.2 | Other seasonal allergic rhinitis |
| J30.5 | Allergic rhinitis due to food |
| J30.81 | Allergic rhinitis due to animal (cat) (dog) hair and dander |
| J30.89 | Other allergic rhinitis |
| J30.9 | Allergic rhinitis, unspecified |
| J31.0 | Chronic rhinitis |
| J32.0 | Chronic maxillary sinusitis |
| J32.1 | Chronic frontal sinusitis |
| J32.2 | Chronic ethmoidal sinusitis |
| J32.3 | Chronic sphenoidal sinusitis |
| J45.20 | Mild intermittent asthma, uncomplicated |
| J45.21 | Mild intermittent asthma with (acute) exacerbation |
| J45.22 | Mild intermittent asthma with status asthmaticus |
| J45.30 | Mild persistent asthma, uncomplicated |
| J45.31 | Mild persistent asthma with (acute) exacerbation |
| J45.32 | Mild persistent asthma with status asthmaticus |
| J45.40 | Moderate persistent asthma, uncomplicated |
| J45.41 | Moderate persistent asthma with (acute) exacerbation |
| J45.42 | Moderate persistent asthma with status asthmaticus |
| J45.50 | Severe persistent asthma, uncomplicated |
| J45.51 | Severe persistent asthma with (acute) exacerbation |
| J45.52 | Severe persistent asthma with status asthmaticus |
| J45.901 | Unspecified asthma with (acute) exacerbation |
| J45.902 | Unspecified asthma with status asthmaticus |
| J45.909 | Unspecified asthma, uncomplicated |
| J45.991 | Cough variant asthma |
| J45.998 | Other asthma |
| L20.0 | Besnier's prurigo |
| L20.81 | Atopic neurodermatitis |
| L20.82 | Flexural eczema |
| L20.84 | Intrinsic (allergic) eczema |
| L20.89 | Other atopic dermatitis |
| L23.0 | Allergic contact dermatitis due to metals |
| L23.1 | Allergic contact dermatitis due to adhesives |
| L23.2 | Allergic contact dermatitis due to cosmetics |
| L23.3 | Allergic contact dermatitis due to drugs in contact with skin |
| L23.4 | Allergic contact dermatitis due to dyes |
| L23.5 | Allergic contact dermatitis due to other chemical products |
| L23.6 | Allergic contact dermatitis due to food in contact with the skin |
| L23.7 | Allergic contact dermatitis due to plants, except food |
| L23.81 | Allergic contact dermatitis due to animal (cat) (dog) dander |
| L23.89 | Allergic contact dermatitis due to other agents |
| L23.9 | Allergic contact dermatitis, unspecified cause |
| L24.0 | Irritant contact dermatitis due to detergents |
| L24.1 | Irritant contact dermatitis due to oils and greases |
| L24.2 | Irritant contact dermatitis due to solvents |
| L24.3 | Irritant contact dermatitis due to cosmetics |
| L24.4 | Irritant contact dermatitis due to drugs in contact with skin |
| L24.5 | Irritant contact dermatitis due to other chemical products |
| L24.6 | Irritant contact dermatitis due to food in contact with skin |
| L24.7 | Irritant contact dermatitis due to plants, except food |
| L24.81 | Irritant contact dermatitis due to metals |
| L24.89 | Irritant contact dermatitis due to other agents |
| L24.9 | Irritant contact dermatitis, unspecified cause |
| L25.0 | Unspecified contact dermatitis due to cosmetics |
| L25.1 | Unspecified contact dermatitis due to drugs in contact with skin |
| L25.2 | Unspecified contact dermatitis due to dyes |
| L25.3 | Unspecified contact dermatitis due to other chemical products |
| L25.4 | Unspecified contact dermatitis due to food in contact with skin |
| L25.5 | Unspecified contact dermatitis due to plants, except food |
| L25.8 | Unspecified contact dermatitis due to other agents |
| L25.9 | Unspecified contact dermatitis, unspecified cause |
| L27.2 | Dermatitis due to ingested food |
| L30.8 | Other specified dermatitis |
| L50.0 | Allergic urticaria |
| L50.1 | Idiopathic urticaria |
| L50.3 | Dermatographic urticaria |
| L50.6 | Contact urticaria |
| L50.8 | Other urticaria |
| R05.3 | Chronic cough |
| T36.0X5A | Adverse effect of penicillins, initial encounter |
| T36.0X5D | Adverse effect of penicillins, subsequent encounter |
| T36.0X5S | Adverse effect of penicillins, sequela |
| T36.1X5A | Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter |
| T36.1X5D | Adverse effect of cephalosporins and other beta-lactam antibiotics, subsequent encounter |
| T36.1X5S | Adverse effect of cephalosporins and other beta-lactam antibiotics, sequela |
| T36.2X5A | Adverse effect of chloramphenicol group, initial encounter |
| T36.2X5D | Adverse effect of chloramphenicol group, subsequent encounter |
| T36.2X5S | Adverse effect of chloramphenicol group, sequela |
| T36.3X5A | Adverse effect of macrolides, initial encounter |
| T36.3X5D | Adverse effect of macrolides, subsequent encounter |
| T36.3X5S | Adverse effect of macrolides, sequela |
| T36.4X5A | Adverse effect of tetracyclines, initial encounter |
| T36.4X5D | Adverse effect of tetracyclines, subsequent encounter |
| T36.4X5S | Adverse effect of tetracyclines, sequela |
| T36.5X5A | Adverse effect of aminoglycosides, initial encounter |
| T36.5X5D | Adverse effect of aminoglycosides, subsequent encounter |
| T36.5X5S | Adverse effect of aminoglycosides, sequela |
| T36.6X5A | Adverse effect of rifampicins, initial encounter |
| T36.6X5D | Adverse effect of rifampicins, subsequent encounter |
| T36.6X5S | Adverse effect of rifampicins, sequela |
| T36.7X5A | Adverse effect of antifungal antibiotics, systemically used, initial encounter |
| T36.7X5D | Adverse effect of antifungal antibiotics, systemically used, subsequent encounter |
| T36.7X5S | Adverse effect of antifungal antibiotics, systemically used, sequela |
| T36.8X5A | Adverse effect of other systemic antibiotics, initial encounter |
| T36.8X5D | Adverse effect of other systemic antibiotics, subsequent encounter |
| T36.8X5S | Adverse effect of other systemic antibiotics, sequela |
| T36.AX5A | Adverse effect of fluoroquinolone antibiotics, initial encounter |
| T36.AX5D | Adverse effect of fluoroquinolone antibiotics, subsequent encounter |
| T36.AX5S | Adverse effect of fluoroquinolone antibiotics, sequela |
| T37.0X5A | Adverse effect of sulfonamides, initial encounter |
| T37.0X5D | Adverse effect of sulfonamides, subsequent encounter |
| T37.0X5S | Adverse effect of sulfonamides, sequela |
| T37.1X5A | Adverse effect of antimycobacterial drugs, initial encounter |
| T37.1X5D | Adverse effect of antimycobacterial drugs, subsequent encounter |
| T37.1X5S | Adverse effect of antimycobacterial drugs, sequela |
| T37.2X5A | Adverse effect of antimalarials and drugs acting on other blood protozoa, initial encounter |
| T37.2X5D | Adverse effect of antimalarials and drugs acting on other blood protozoa, subsequent encounter |
| T37.2X5S | Adverse effect of antimalarials and drugs acting on other blood protozoa, sequela |
| T37.3X5A | Adverse effect of other antiprotozoal drugs, initial encounter |
| T37.3X5D | Adverse effect of other antiprotozoal drugs, subsequent encounter |
| T37.3X5S | Adverse effect of other antiprotozoal drugs, sequela |
| T37.4X5A | Adverse effect of anthelminthics, initial encounter |
| T37.4X5D | Adverse effect of anthelminthics, subsequent encounter |
| T37.4X5S | Adverse effect of anthelminthics, sequela |
| T37.5X5A | Adverse effect of antiviral drugs, initial encounter |
| T37.5X5D | Adverse effect of antiviral drugs, subsequent encounter |
| T37.5X5S | Adverse effect of antiviral drugs, sequela |
| T37.8X5A | Adverse effect of other specified systemic anti-infectives and antiparasitics, initial encounter |
| T37.8X5D | Adverse effect of other specified systemic anti-infectives and antiparasitics, subsequent encounter |
| T37.8X5S | Adverse effect of other specified systemic anti-infectives and antiparasitics, sequela |
| T38.0X5A | Adverse effect of glucocorticoids and synthetic analogues, initial encounter |
| T38.0X5D | Adverse effect of glucocorticoids and synthetic analogues, subsequent encounter |
| T38.0X5S | Adverse effect of glucocorticoids and synthetic analogues, sequela |
| T38.1X5A | Adverse effect of thyroid hormones and substitutes, initial encounter |
| T38.1X5D | Adverse effect of thyroid hormones and substitutes, subsequent encounter |
| T38.1X5S | Adverse effect of thyroid hormones and substitutes, sequela |
| T38.2X5A | Adverse effect of antithyroid drugs, initial encounter |
| T38.2X5D | Adverse effect of antithyroid drugs, subsequent encounter |
| T38.2X5S | Adverse effect of antithyroid drugs, sequela |
| T38.3X5A | Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter |
| T38.3X5D | Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, subsequent encounter |
| T38.3X5S | Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, sequela |
| T38.4X5A | Adverse effect of oral contraceptives, initial encounter |
| T38.4X5D | Adverse effect of oral contraceptives, subsequent encounter |
| T38.4X5S | Adverse effect of oral contraceptives, sequela |
| T38.5X5A | Adverse effect of other estrogens and progestogens, initial encounter |
| T38.5X5D | Adverse effect of other estrogens and progestogens, subsequent encounter |
| T38.5X5S | Adverse effect of other estrogens and progestogens, sequela |
| T38.6X5A | Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, initial encounter |
| T38.6X5D | Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, subsequent encounter |
| T38.6X5S | Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, sequela |
| T38.7X5A | Adverse effect of androgens and anabolic congeners, initial encounter |
| T38.7X5D | Adverse effect of androgens and anabolic congeners, subsequent encounter |
| T38.7X5S | Adverse effect of androgens and anabolic congeners, sequela |
| T38.815A | Adverse effect of anterior pituitary [adenohypophyseal] hormones, initial encounter |
| T38.815D | Adverse effect of anterior pituitary [adenohypophyseal] hormones, subsequent encounter |
| T38.815S | Adverse effect of anterior pituitary [adenohypophyseal] hormones, sequela |
| T38.895A | Adverse effect of other hormones and synthetic substitutes, initial encounter |
| T38.895D | Adverse effect of other hormones and synthetic substitutes, subsequent encounter |
| T38.895S | Adverse effect of other hormones and synthetic substitutes, sequela |
| T38.995A | Adverse effect of other hormone antagonists, initial encounter |
| T38.995D | Adverse effect of other hormone antagonists, subsequent encounter |
| T38.995S | Adverse effect of other hormone antagonists, sequela |
| T39.015A | Adverse effect of aspirin, initial encounter |
| T39.015D | Adverse effect of aspirin, subsequent encounter |
| T39.015S | Adverse effect of aspirin, sequela |
| T39.095A | Adverse effect of salicylates, initial encounter |
| T39.095D | Adverse effect of salicylates, subsequent encounter |
| T39.095S | Adverse effect of salicylates, sequela |
| T39.1X5A | Adverse effect of 4-Aminophenol derivatives, initial encounter |
| T39.1X5D | Adverse effect of 4-Aminophenol derivatives, subsequent encounter |
| T39.1X5S | Adverse effect of 4-Aminophenol derivatives, sequela |
| T39.2X5A | Adverse effect of pyrazolone derivatives, initial encounter |
| T39.2X5D | Adverse effect of pyrazolone derivatives, subsequent encounter |
| T39.2X5S | Adverse effect of pyrazolone derivatives, sequela |
| T39.315A | Adverse effect of propionic acid derivatives, initial encounter |
| T39.315D | Adverse effect of propionic acid derivatives, subsequent encounter |
| T39.315S | Adverse effect of propionic acid derivatives, sequela |
| T39.395A | Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter |
| T39.395D | Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], subsequent encounter |
| T39.395S | Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], sequela |
| T39.4X5A | Adverse effect of antirheumatics, not elsewhere classified, initial encounter |
| T39.4X5D | Adverse effect of antirheumatics, not elsewhere classified, subsequent encounter |
| T39.4X5S | Adverse effect of antirheumatics, not elsewhere classified, sequela |
| T39.8X5A | Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter |
| T39.8X5D | Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, subsequent encounter |
| T39.8X5S | Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, sequela |
| T44.3X5A | Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter |
| T44.3X5D | Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter |
| T44.3X5S | Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela |
| T44.4X5A | Adverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter |
| T44.4X5D | Adverse effect of predominantly alpha-adrenoreceptor agonists, subsequent encounter |
| T44.4X5S | Adverse effect of predominantly alpha-adrenoreceptor agonists, sequela |
| T44.5X5A | Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter |
| T44.5X5D | Adverse effect of predominantly beta-adrenoreceptor agonists, subsequent encounter |
| T44.5X5S | Adverse effect of predominantly beta-adrenoreceptor agonists, sequela |
| T44.6X5A | Adverse effect of alpha-adrenoreceptor antagonists, initial encounter |
| T44.6X5D | Adverse effect of alpha-adrenoreceptor antagonists, subsequent encounter |
| T44.6X5S | Adverse effect of alpha-adrenoreceptor antagonists, sequela |
| T44.7X5A | Adverse effect of beta-adrenoreceptor antagonists, initial encounter |
| T44.7X5D | Adverse effect of beta-adrenoreceptor antagonists, subsequent encounter |
| T44.7X5S | Adverse effect of beta-adrenoreceptor antagonists, sequela |
| T44.8X5A | Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter |
| T44.8X5D | Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, subsequent encounter |
| T44.8X5S | Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, sequela |
| T44.995A | Adverse effect of other drug primarily affecting the autonomic nervous system, initial encounter |
| T44.995D | Adverse effect of other drug primarily affecting the autonomic nervous system, subsequent encounter |
| T44.995S | Adverse effect of other drug primarily affecting the autonomic nervous system, sequela |
| T45.0X5A | Adverse effect of antiallergic and antiemetic drugs, initial encounter |
| T45.0X5D | Adverse effect of antiallergic and antiemetic drugs, subsequent encounter |
| T45.0X5S | Adverse effect of antiallergic and antiemetic drugs, sequela |
| T45.1X5A | Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter |
| T45.1X5D | Adverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter |
| T45.1X5S | Adverse effect of antineoplastic and immunosuppressive drugs, sequela |
| T45.2X5A | Adverse effect of vitamins, initial encounter |
| T45.2X5D | Adverse effect of vitamins, subsequent encounter |
| T45.2X5S | Adverse effect of vitamins, sequela |
| T45.3X5A | Adverse effect of enzymes, initial encounter |
| T45.3X5D | Adverse effect of enzymes, subsequent encounter |
| T45.3X5S | Adverse effect of enzymes, sequela |
| T45.4X5A | Adverse effect of iron and its compounds, initial encounter |
| T45.4X5D | Adverse effect of iron and its compounds, subsequent encounter |
| T45.4X5S | Adverse effect of iron and its compounds, sequela |
| T45.515A | Adverse effect of anticoagulants, initial encounter |
| T45.515D | Adverse effect of anticoagulants, subsequent encounter |
| T45.515S | Adverse effect of anticoagulants, sequela |
| T45.525A | Adverse effect of antithrombotic drugs, initial encounter |
| T45.525D | Adverse effect of antithrombotic drugs, subsequent encounter |
| T45.525S | Adverse effect of antithrombotic drugs, sequela |
| T45.615A | Adverse effect of thrombolytic drugs, initial encounter |
| T45.615D | Adverse effect of thrombolytic drugs, subsequent encounter |
| T45.615S | Adverse effect of thrombolytic drugs, sequela |
| T45.625A | Adverse effect of hemostatic drug, initial encounter |
| T45.625D | Adverse effect of hemostatic drug, subsequent encounter |
| T45.625S | Adverse effect of hemostatic drug, sequela |
| T45.695A | Adverse effect of other fibrinolysis-affecting drugs, initial encounter |
| T45.695D | Adverse effect of other fibrinolysis-affecting drugs, subsequent encounter |
| T45.695S | Adverse effect of other fibrinolysis-affecting drugs, sequela |
| T45.7X5A | Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, initial encounter |
| T45.7X5D | Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, subsequent encounter |
| T45.7X5S | Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, sequela |
| T45.8X5A | Adverse effect of other primarily systemic and hematological agents, initial encounter |
| T45.8X5D | Adverse effect of other primarily systemic and hematological agents, subsequent encounter |
| T45.8X5S | Adverse effect of other primarily systemic and hematological agents, sequela |
| T45.AX5A | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, initial encounter |
| T45.AX5D | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, subsequent encounter |
| T45.AX5S | Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, sequela |
| T46.0X5A | Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter |
| T46.0X5D | Adverse effect of cardiac-stimulant glycosides and drugs of similar action, subsequent encounter |
| T46.0X5S | Adverse effect of cardiac-stimulant glycosides and drugs of similar action, sequela |
| T46.1X5A | Adverse effect of calcium-channel blockers, initial encounter |
| T46.1X5D | Adverse effect of calcium-channel blockers, subsequent encounter |
| T46.1X5S | Adverse effect of calcium-channel blockers, sequela |
| T46.2X5A | Adverse effect of other antidysrhythmic drugs, initial encounter |
| T46.2X5D | Adverse effect of other antidysrhythmic drugs, subsequent encounter |
| T46.2X5S | Adverse effect of other antidysrhythmic drugs, sequela |
| T46.3X5A | Adverse effect of coronary vasodilators, initial encounter |
| T46.3X5D | Adverse effect of coronary vasodilators, subsequent encounter |
| T46.3X5S | Adverse effect of coronary vasodilators, sequela |
| T46.4X5A | Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter |
| T46.4X5D | Adverse effect of angiotensin-converting-enzyme inhibitors, subsequent encounter |
| T46.4X5S | Adverse effect of angiotensin-converting-enzyme inhibitors, sequela |
| T46.5X5A | Adverse effect of other antihypertensive drugs, initial encounter |
| T46.5X5D | Adverse effect of other antihypertensive drugs, subsequent encounter |
| T46.5X5S | Adverse effect of other antihypertensive drugs, sequela |
| T46.6X5A | Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter |
| T46.6X5D | Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, subsequent encounter |
| T46.6X5S | Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, sequela |
| T46.7X5A | Adverse effect of peripheral vasodilators, initial encounter |
| T46.7X5D | Adverse effect of peripheral vasodilators, subsequent encounter |
| T46.7X5S | Adverse effect of peripheral vasodilators, sequela |
| T46.8X5A | Adverse effect of antivaricose drugs, including sclerosing agents, initial encounter |
| T46.8X5D | Adverse effect of antivaricose drugs, including sclerosing agents, subsequent encounter |
| T46.8X5S | Adverse effect of antivaricose drugs, including sclerosing agents, sequela |
| T46.995A | Adverse effect of other agents primarily affecting the cardiovascular system, initial encounter |
| T46.995D | Adverse effect of other agents primarily affecting the cardiovascular system, subsequent encounter |
| T46.995S | Adverse effect of other agents primarily affecting the cardiovascular system, sequela |
| T47.0X5A | Adverse effect of histamine H2-receptor blockers, initial encounter |
| T47.0X5D | Adverse effect of histamine H2-receptor blockers, subsequent encounter |
| T47.0X5S | Adverse effect of histamine H2-receptor blockers, sequela |
| T47.1X5A | Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter |
| T47.1X5D | Adverse effect of other antacids and anti-gastric-secretion drugs, subsequent encounter |
| T47.1X5S | Adverse effect of other antacids and anti-gastric-secretion drugs, sequela |
| T47.2X5A | Adverse effect of stimulant laxatives, initial encounter |
| T47.2X5D | Adverse effect of stimulant laxatives, subsequent encounter |
| T47.2X5S | Adverse effect of stimulant laxatives, sequela |
| T47.3X5A | Adverse effect of saline and osmotic laxatives, initial encounter |
| T47.3X5D | Adverse effect of saline and osmotic laxatives, subsequent encounter |
| T47.3X5S | Adverse effect of saline and osmotic laxatives, sequela |
| T47.4X5A | Adverse effect of other laxatives, initial encounter |
| T47.4X5D | Adverse effect of other laxatives, subsequent encounter |
| T47.4X5S | Adverse effect of other laxatives, sequela |
| T47.5X5A | Adverse effect of digestants, initial encounter |
| T47.5X5D | Adverse effect of digestants, subsequent encounter |
| T47.5X5S | Adverse effect of digestants, sequela |
| T47.6X5A | Adverse effect of antidiarrheal drugs, initial encounter |
| T47.6X5D | Adverse effect of antidiarrheal drugs, subsequent encounter |
| T47.6X5S | Adverse effect of antidiarrheal drugs, sequela |
| T47.7X5A | Adverse effect of emetics, initial encounter |
| T47.7X5D | Adverse effect of emetics, subsequent encounter |
| T47.7X5S | Adverse effect of emetics, sequela |
| T47.8X5A | Adverse effect of other agents primarily affecting gastrointestinal system, initial encounter |
| T47.8X5D | Adverse effect of other agents primarily affecting gastrointestinal system, subsequent encounter |
| T47.8X5S | Adverse effect of other agents primarily affecting gastrointestinal system, sequela |
| T48.0X5A | Adverse effect of oxytocic drugs, initial encounter |
| T48.0X5D | Adverse effect of oxytocic drugs, subsequent encounter |
| T48.0X5S | Adverse effect of oxytocic drugs, sequela |
| T48.1X5A | Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter |
| T48.1X5D | Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], subsequent encounter |
| T48.1X5S | Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], sequela |
| T48.295A | Adverse effect of other drugs acting on muscles, initial encounter |
| T48.295D | Adverse effect of other drugs acting on muscles, subsequent encounter |
| T48.295S | Adverse effect of other drugs acting on muscles, sequela |
| T48.3X5A | Adverse effect of antitussives, initial encounter |
| T48.3X5D | Adverse effect of antitussives, subsequent encounter |
| T48.3X5S | Adverse effect of antitussives, sequela |
| T48.4X5A | Adverse effect of expectorants, initial encounter |
| T48.4X5D | Adverse effect of expectorants, subsequent encounter |
| T48.4X5S | Adverse effect of expectorants, sequela |
| T48.5X5A | Adverse effect of other anti-common-cold drugs, initial encounter |
| T48.5X5D | Adverse effect of other anti-common-cold drugs, subsequent encounter |
| T48.5X5S | Adverse effect of other anti-common-cold drugs, sequela |
| T48.6X5A | Adverse effect of antiasthmatics, initial encounter |
| T48.6X5D | Adverse effect of antiasthmatics, subsequent encounter |
| T48.6X5S | Adverse effect of antiasthmatics, sequela |
| T48.995A | Adverse effect of other agents primarily acting on the respiratory system, initial encounter |
| T48.995D | Adverse effect of other agents primarily acting on the respiratory system, subsequent encounter |
| T48.995S | Adverse effect of other agents primarily acting on the respiratory system, sequela |
| T49.5X5A | Adverse effect of ophthalmological drugs and preparations, initial encounter |
| T49.5X5D | Adverse effect of ophthalmological drugs and preparations, subsequent encounter |
| T49.5X5S | Adverse effect of ophthalmological drugs and preparations, sequela |
| T50.0X5A | Adverse effect of mineralocorticoids and their antagonists, initial encounter |
| T50.0X5D | Adverse effect of mineralocorticoids and their antagonists, subsequent encounter |
| T50.0X5S | Adverse effect of mineralocorticoids and their antagonists, sequela |
| T50.1X5A | Adverse effect of loop [high-ceiling] diuretics, initial encounter |
| T50.1X5D | Adverse effect of loop [high-ceiling] diuretics, subsequent encounter |
| T50.1X5S | Adverse effect of loop [high-ceiling] diuretics, sequela |
| T50.2X5A | Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter |
| T50.2X5D | Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, subsequent encounter |
| T50.2X5S | Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, sequela |
| T50.3X5A | Adverse effect of electrolytic, caloric and water-balance agents, initial encounter |
| T50.3X5D | Adverse effect of electrolytic, caloric and water-balance agents, subsequent encounter |
| T50.3X5S | Adverse effect of electrolytic, caloric and water-balance agents, sequela |
| T50.4X5A | Adverse effect of drugs affecting uric acid metabolism, initial encounter |
| T50.4X5D | Adverse effect of drugs affecting uric acid metabolism, subsequent encounter |
| T50.4X5S | Adverse effect of drugs affecting uric acid metabolism, sequela |
| T50.5X5A | Adverse effect of appetite depressants, initial encounter |
| T50.5X5D | Adverse effect of appetite depressants, subsequent encounter |
| T50.5X5S | Adverse effect of appetite depressants, sequela |
| T50.7X5A | Adverse effect of analeptics and opioid receptor antagonists, initial encounter |
| T50.7X5D | Adverse effect of analeptics and opioid receptor antagonists, subsequent encounter |
| T50.7X5S | Adverse effect of analeptics and opioid receptor antagonists, sequela |
| T50.8X5A | Adverse effect of diagnostic agents, initial encounter |
| T50.8X5D | Adverse effect of diagnostic agents, subsequent encounter |
| T50.8X5S | Adverse effect of diagnostic agents, sequela |
| T50.995A | Adverse effect of other drugs, medicaments and biological substances, initial encounter |
| T50.995D | Adverse effect of other drugs, medicaments and biological substances, subsequent encounter |
| T50.995S | Adverse effect of other drugs, medicaments and biological substances, sequela |
| T50.A15A | Adverse effect of pertussis vaccine, including combinations with a pertussis component, initial encounter |
| T50.A15D | Adverse effect of pertussis vaccine, including combinations with a pertussis component, subsequent encounter |
| T50.A15S | Adverse effect of pertussis vaccine, including combinations with a pertussis component, sequela |
| T50.A25A | Adverse effect of mixed bacterial vaccines without a pertussis component, initial encounter |
| T50.A25D | Adverse effect of mixed bacterial vaccines without a pertussis component, subsequent encounter |
| T50.A25S | Adverse effect of mixed bacterial vaccines without a pertussis component, sequela |
| T50.A95A | Adverse effect of other bacterial vaccines, initial encounter |
| T50.A95D | Adverse effect of other bacterial vaccines, subsequent encounter |
| T50.A95S | Adverse effect of other bacterial vaccines, sequela |
| T50.B95A | Adverse effect of other viral vaccines, initial encounter |
| T50.B95D | Adverse effect of other viral vaccines, subsequent encounter |
| T50.B95S | Adverse effect of other viral vaccines, sequela |
| T50.Z15A | Adverse effect of immunoglobulin, initial encounter |
| T50.Z15D | Adverse effect of immunoglobulin, subsequent encounter |
| T50.Z15S | Adverse effect of immunoglobulin, sequela |
| T50.Z95A | Adverse effect of other vaccines and biological substances, initial encounter |
| T50.Z95D | Adverse effect of other vaccines and biological substances, subsequent encounter |
| T50.Z95S | Adverse effect of other vaccines and biological substances, sequela |
| T63.421A | Toxic effect of venom of ants, accidental (unintentional), initial encounter |
| T63.421D | Toxic effect of venom of ants, accidental (unintentional), subsequent encounter |
| T63.421S | Toxic effect of venom of ants, accidental (unintentional), sequela |
| T63.422A | Toxic effect of venom of ants, intentional self-harm, initial encounter |
| T63.422D | Toxic effect of venom of ants, intentional self-harm, subsequent encounter |
| T63.422S | Toxic effect of venom of ants, intentional self-harm, sequela |
| T63.423A | Toxic effect of venom of ants, assault, initial encounter |
| T63.423D | Toxic effect of venom of ants, assault, subsequent encounter |
| T63.423S | Toxic effect of venom of ants, assault, sequela |
| T63.424A | Toxic effect of venom of ants, undetermined, initial encounter |
| T63.424D | Toxic effect of venom of ants, undetermined, subsequent encounter |
| T63.424S | Toxic effect of venom of ants, undetermined, sequela |
| T63.431A | Toxic effect of venom of caterpillars, accidental (unintentional), initial encounter |
| T63.431D | Toxic effect of venom of caterpillars, accidental (unintentional), subsequent encounter |
| T63.431S | Toxic effect of venom of caterpillars, accidental (unintentional), sequela |
| T63.432A | Toxic effect of venom of caterpillars, intentional self-harm, initial encounter |
| T63.432D | Toxic effect of venom of caterpillars, intentional self-harm, subsequent encounter |
| T63.432S | Toxic effect of venom of caterpillars, intentional self-harm, sequela |
| T63.433A | Toxic effect of venom of caterpillars, assault, initial encounter |
| T63.433D | Toxic effect of venom of caterpillars, assault, subsequent encounter |
| T63.433S | Toxic effect of venom of caterpillars, assault, sequela |
| T63.434A | Toxic effect of venom of caterpillars, undetermined, initial encounter |
| T63.434D | Toxic effect of venom of caterpillars, undetermined, subsequent encounter |
Showing the first 400 of 569 covered codes — this procedure has a large covered-diagnosis set; see the governing LCD/article for the complete list.
Frequently asked questions
Which ICD-10 codes support medical necessity for CPT 0178U?
Medicare coverage policies (LCDs/NCDs and Billing & Coding articles) list 569 ICD-10 diagnosis codes that support medical necessity for CPT 0178U. The covered codes are listed on this page. Coverage varies by MAC/state — always confirm against the policy that applies to you.
What is a medical-necessity (LCD/NCD) crosswalk?
A claim whose procedure isn't supported by a covered diagnosis denies as "not medically necessary" (CARC 50). CMS coverage policies define which diagnoses justify a procedure; this page is the ICD-10 → CPT 0178U view of that relationship.
Catch medical-necessity denials before you bill. CareNiva scrubs claims against LCD/NCD coverage and flags unsupported diagnoses — in the same platform you run visits and billing.
More free billing tools: all crosswalks · NCCI edits · Medicare fees · denial codes
Informational only, not coding, billing, or legal advice. Based on CMS Medicare Coverage Database data; verify the current LCD/NCD for your MAC before billing.
Bill it right the first time
Join providers across the country delivering modern virtual care with CareNiva. Free to start, ready in minutes.
100% Satisfaction Guaranteed — try it risk-free